Standard Dose Bevacizumab

DRUG2 trials

Sponsors

M.D. Anderson Cancer Center, David Peereboom

Conditions

Brain CancerGlioblastoma

Phase 2

Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)

CompletedNCT01067469

M.D. Anderson Cancer CenterBrain Cancer, Glioblastoma

Start: 2010-01-31End: 2016-10-31Updated: 2020-03-17

Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM

Active, not recruitingNCT03452579

David PeereboomGlioblastoma

Start: 2018-05-21End: 2025-06-30Updated: 2025-02-28

Related Papers

A randomized, controlled, phase 2 trial of nivolumab plus standard-dose or low-dose bevacizumab for recurrent glioblastoma (NAVAL).

Journal of Clinical Oncology2024-06-014 citations

Randomized phase 2 study of nivolumab (nivo) plus either standard or reduced dose bevacizumab (bev) in recurrent glioblastoma (rGBM).

Journal of Clinical Oncology2021-05-2014 citations

RBTT-08. A RANDOMIZED PHASE 2 OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VERSUS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA (GBM)

Neuro-Oncology2019-11-01

ATIM-40. CIRCULATING MYELOID-DERIVED SUPPRESSOR CELLS PREDICT FAVORABLE RESPONSE TO IMMUNE CHECKPOINT THERAPY IN A RANDOMIZED TRIAL OF NIVOLUMAB AND BEVACIZUMAB IN RECURRENT GBM

Neuro-Oncology2019-11-01

RBTT-01. RANDOMIZED PHASE 2 OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VERSUS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA

Neuro-Oncology2018-11-015 citations

A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma.

Journal of Clinical Oncology2015-05-206 citations